SPBC1861.04c Antibody

What is SPBC1861.04c and why is it important in research?

SPBC1861.04c refers to an RNA-binding protein Prp24 (predicted) found in Schizosaccharomyces pombe (fission yeast). This protein plays a significant role in RNA processing mechanisms. The antibody against this protein is important for investigating RNA metabolism, splicing mechanisms, and cellular processes in S. pombe, which serves as an excellent model organism for eukaryotic cell biology. The protein is officially named as "RNA-binding protein Prp24 (predicted)" according to NCBI, while UniProt identifies it as "Uncharacterized RNA-binding protein C1861.04c" . Research into this protein contributes to our understanding of fundamental RNA processing mechanisms across eukaryotes.

What are the primary experimental applications for SPBC1861.04c antibody?

The SPBC1861.04c antibody has been validated for several key applications in molecular biology research, including:

• ELISA (Enzyme-Linked Immunosorbent Assay) for quantitative protein detection

• Western Blot analysis for identification and semi-quantitative analysis of the target protein

• Immunoprecipitation for protein complex isolation

• Immunofluorescence for subcellular localization studies

When designing experiments, researchers should ensure proper validation controls are implemented, particularly when using the antibody for novel applications beyond those already established. Cross-reactivity testing is essential when working with related species or protein families to ensure specificity of results.

How does SPBC1861.04c antibody compare to other RNA-binding protein antibodies?

SPBC1861.04c antibody is specific to the Prp24 RNA-binding protein in S. pombe. Unlike antibodies targeting more conserved RNA-binding domains, this antibody offers high specificity for S. pombe research. When comparing to antibodies against related proteins like those in the study of SARS-CoV-2 neutralizing antibodies, the screening methodologies share similarities but differ in target specificity . For investigators working across multiple model systems, cross-reactivity testing is essential, as even closely related proteins in different yeast species may not be recognized by this antibody. The polyclonal nature of commercially available SPBC1861.04c antibodies provides recognition of multiple epitopes, which can be advantageous for detection sensitivity but may introduce background issues not seen with monoclonal alternatives targeting well-characterized epitopes.

What are the optimal conditions for using SPBC1861.04c antibody in Western blotting?

For optimal Western blot results with SPBC1861.04c antibody, consider the following methodology:

• Sample preparation: Extract proteins from S. pombe using a buffer containing protease inhibitors to prevent degradation of the target protein.

• Gel electrophoresis: Use 10-12% SDS-PAGE gels for optimal separation of the target protein (approximately 55 kDa).

• Transfer conditions: Semi-dry transfer at 15V for 45 minutes or wet transfer at 30V overnight at 4°C.

• Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute SPBC1861.04c antibody at 1:1000 to 1:2000 in blocking buffer and incubate overnight at 4°C.

• Washing: Perform 4-5 washes with TBST, 5 minutes each.

• Secondary antibody: Use anti-rabbit HRP-conjugated secondary antibody at 1:5000 dilution for 1 hour at room temperature.

• Detection: Enhanced chemiluminescence methods are recommended for optimal signal-to-noise ratio .

Critical validation controls should include lysates from SPBC1861.04c knockout strains and pre-immune serum controls to verify specificity of the detected bands.

How should SPBC1861.04c antibody be stored and handled to maintain activity?

To maintain optimal antibody activity:

• Long-term storage: Store aliquoted antibody at -20°C or -80°C to avoid repeated freeze-thaw cycles. Glycerol (50%) can be added for cryoprotection.

• Working solution: Refrigerate at 4°C for up to 2 weeks.

• Avoid contamination: Use sterile conditions when handling the antibody.

• Freeze-thaw cycles: Minimize to fewer than 5 cycles to prevent denaturation.

• Centrifuge briefly before opening to collect all liquid at the bottom of the tube.

• Consider adding preservatives (0.02% sodium azide) for longer-term storage at 4°C.

• Monitor activity periodically using positive controls to ensure the antibody remains functional .

Rapid temperature changes should be avoided, and the antibody should equilibrate to room temperature before use without heating.

What controls are essential when working with SPBC1861.04c antibody?

Essential controls for experiments involving SPBC1861.04c antibody include:

• Positive control: Lysate from wild-type S. pombe cells known to express SPBC1861.04c.

• Negative control: Lysate from SPBC1861.04c deletion strains or knockout mutants.

• Isotype control: Use of rabbit IgG at the same concentration to detect non-specific binding.

• Pre-absorption control: Pre-incubating the antibody with recombinant SPBC1861.04c protein to confirm specificity.

• Loading control: Detection of a housekeeping protein to normalize expression levels.

• Secondary antibody-only control: To detect non-specific binding of the secondary antibody.

• Cross-reactivity controls: Testing the antibody against related proteins or in different species when applicable .

For immunolocalization studies, additional controls like peptide competition assays may be necessary to confirm the specificity of observed staining patterns.

How can SPBC1861.04c antibody be used to investigate RNA processing complexes?

To investigate RNA processing complexes using SPBC1861.04c antibody:

• Co-immunoprecipitation (Co-IP): Use the antibody to pull down SPBC1861.04c and its interacting partners, followed by mass spectrometry identification.

  • Cross-linking prior to lysis may help preserve transient interactions.

  • RNase treatment controls can distinguish RNA-dependent from direct protein interactions.

• Chromatin Immunoprecipitation (ChIP): Adapt standard ChIP protocols to investigate RNA-protein interactions (RIP) or use CLIP (Cross-Linking Immunoprecipitation) methods.

  • Include controls for non-specific RNA binding.

  • Consider formaldehyde cross-linking to capture in vivo interactions.

• Immunofluorescence combined with RNA FISH: Determine the co-localization of SPBC1861.04c with specific RNA transcripts.

  • Include appropriate channel bleed-through controls.

  • Consider super-resolution techniques for detailed co-localization analysis.

• Proximity ligation assays: Investigate protein-protein interactions within RNA processing complexes.

  • Negative controls using antibodies against non-interacting proteins are essential .

These approaches should be optimized based on the specific research question, considering factors like cell lysis conditions, salt concentrations, and detergent usage that may affect complex stability.

What methods can be used to study post-translational modifications of SPBC1861.04c using the antibody?

To investigate post-translational modifications (PTMs) of SPBC1861.04c:

• Immunoprecipitation followed by mass spectrometry:

  • Immunoprecipitate SPBC1861.04c using the antibody

  • Perform tryptic digestion of purified protein

  • Analyze peptides by LC-MS/MS to identify PTMs

  • Use phosphatase inhibitors during lysis if studying phosphorylation

• Western blotting with modification-specific detection:

  • Run parallel samples on multiple blots

  • Probe with SPBC1861.04c antibody and with PTM-specific antibodies

  • Consider Phos-tag gels for phosphorylation analysis

• 2D gel electrophoresis:

  • Separate proteins by isoelectric point and molecular weight

  • Different PTM isoforms appear as spot trains

  • Follow with Western blotting using SPBC1861.04c antibody

• Treatment with modifying/demodifying enzymes:

  • Compare untreated samples with those treated with phosphatases, deubiquitinases, etc.

  • Observe mobility shifts by Western blotting

When interpreting results, consider that modifications may alter antibody recognition, potentially leading to false negatives if the epitope is directly affected by the modification.

How can SPBC1861.04c antibody be used in studying cell wall remodeling processes in S. pombe?

Although SPBC1861.04c is primarily characterized as an RNA-binding protein, investigating its potential relationship to cell wall processes requires specialized approaches:

• Immunofluorescence microscopy:

  • Co-stain with cell wall markers (like calcofluor white) and SPBC1861.04c antibody

  • Analyze localization during different cell cycle stages, particularly during septum formation

  • Compare localization patterns in wild-type cells versus cell wall mutants

• Genetic interaction studies:

  • Compare SPBC1861.04c localization and expression in wild-type versus cell wall mutant backgrounds

  • Construct double mutants between SPBC1861.04c and known cell wall genes

  • Use the antibody to detect expression changes in response to cell wall stress

• Biochemical fractionation:

  • Isolate cell wall fractions and cytoplasmic fractions

  • Analyze SPBC1861.04c distribution using the antibody

  • Identify potential interactions with cell wall synthesis machinery

• Transcriptional regulation:

  • Determine if SPBC1861.04c regulates transcripts encoding cell wall proteins

  • Use RNA-IP to identify bound transcripts, followed by RT-qPCR for cell wall genes

When investigating these relationships, consider that changes in cell wall structure observed in Sup11p depletion experiments might provide insights into broader RNA regulatory networks involving SPBC1861.04c.

What are common troubleshooting steps for weak or absent signal when using SPBC1861.04c antibody?

When troubleshooting weak or absent signals:

• Antibody concentration:

  • Titrate the antibody from 1:500 to 1:5000 to find optimal concentration

  • Consider longer incubation times (overnight at 4°C)

• Protein extraction:

  • Ensure complete lysis using appropriate detergents

  • Add protease inhibitors to prevent degradation

  • Consider different extraction methods (mechanical disruption, enzymatic cell wall digestion)

• Protein denaturation:

  • Adjust sample heating conditions (65°C vs. 95°C)

  • Try different reducing agents (DTT vs. β-mercaptoethanol)

• Detection system:

  • Try more sensitive detection methods (enhanced chemiluminescence)

  • Increase exposure time

  • Consider signal amplification systems

• Blocking conditions:

  • Test different blocking agents (BSA vs. milk)

  • Optimize blocking time and temperature

• Epitope accessibility:

  • Consider native vs. denaturing conditions

  • Try alternative fixation methods for immunofluorescence

  • Test membrane with different pore sizes for Western blotting

Always include positive controls from wild-type S. pombe expressing SPBC1861.04c to validate experimental conditions.

How can researchers differentiate between specific and non-specific binding when using SPBC1861.04c antibody?

To differentiate between specific and non-specific binding:

• Genetic validation:

  • Compare results between wild-type and SPBC1861.04c knockout strains

  • Use CRISPR-Cas9 engineered cell lines with tagged SPBC1861.04c to confirm specificity

• Biochemical validation:

  • Perform peptide competition assays using the immunizing peptide

  • Pre-absorb antibody with recombinant SPBC1861.04c protein

  • Compare staining/detection patterns with antibodies targeting different epitopes of the same protein

• Methodological approaches:

  • Optimize washing conditions (increase stringency with higher salt or detergent)

  • Titrate primary and secondary antibodies to minimize background

  • Use gradient gels to better resolve proteins of similar molecular weight

  • Implement sequential probing strategies to confirm band identity

• Cross-reactivity assessment:

  • Test the antibody against related proteins

  • Check for predicted cross-reactive epitopes using bioinformatics tools

When interpreting results with multiple bands, consider the possibility of splice variants, proteolytic fragments, or post-translationally modified forms of SPBC1861.04c.

How should researchers interpret contradictory results between different detection methods using SPBC1861.04c antibody?

When faced with contradictory results between detection methods:

• Consider epitope accessibility differences:

  • Western blotting detects denatured epitopes that may be inaccessible in native conditions

  • Immunofluorescence preserves cellular context but may mask some epitopes

  • ELISA may detect soluble forms that differ from membrane-bound forms

• Methodological reconciliation:

  • Verify protein extraction efficiency across methods

  • Test multiple fixation and permeabilization protocols for immunofluorescence

  • Compare native versus denaturing conditions in immunoprecipitation

• Technical validation:

  • Implement orthogonal detection methods (mass spectrometry validation)

  • Use multiple antibodies targeting different epitopes

  • Engineer epitope-tagged versions of SPBC1861.04c for validation

• Biological interpretation:

  • Consider subcellular compartmentalization

  • Assess protein complex formation that may mask epitopes

  • Evaluate post-translational modifications affecting antibody recognition

  • Account for cell cycle or stress-dependent changes in localization or expression

Document all experimental conditions thoroughly to identify variables that may explain the discrepancies, such as buffer composition, detection reagents, and sample preparation methods.

How can SPBC1861.04c antibody be integrated with mass spectrometry for comprehensive protein characterization?

Integration of immunological and mass spectrometry approaches:

• Immunoprecipitation-Mass Spectrometry (IP-MS):

  • Perform IP using SPBC1861.04c antibody

  • Separate proteins by SDS-PAGE

  • Excise bands for in-gel digestion

  • Analyze tryptic peptides by LC-MS/MS

  • Consider SILAC or TMT labeling for quantitative analysis

• Targeted MS approaches:

  • Develop Selected/Multiple Reaction Monitoring (SRM/MRM) assays

  • Use antibody-enriched samples for improved sensitivity

  • Create spectral libraries from purified protein

• Structural analysis:

  • Use antibody for protein purification prior to structural studies

  • Identify protease-resistant domains through limited proteolysis followed by MS

  • Map antibody binding sites using hydrogen-deuterium exchange MS

• Post-translational modification mapping:

  • Enrich SPBC1861.04c using the antibody

  • Apply phospho-enrichment strategies (TiO₂, IMAC)

  • Use electron transfer dissociation (ETD) for improved PTM site localization

When combining these techniques, consider using mild elution conditions that preserve protein structure and interactions for downstream MS analysis.

What considerations are important when using SPBC1861.04c antibody in high-throughput screening or multiplexed assays?

For high-throughput or multiplexed applications:

• Antibody validation for high-throughput formats:

  • Verify specificity and sensitivity in multiplex conditions

  • Determine optimal concentrations to minimize cross-reactivity

  • Establish signal-to-noise thresholds specific to multiplex platforms

• Platform-specific considerations:

  • Microarray applications: Test for cross-reactivity with other immobilized proteins

  • Flow cytometry: Optimize fixation and permeabilization for intracellular detection

  • Bead-based assays: Validate coupling efficiency and stability

• Quantification standards:

  • Develop calibration curves using recombinant standards

  • Include inter-plate controls for normalization

  • Implement statistical methods for correcting batch effects

• Assay robustness:

  • Assess Z-factor to determine assay quality

  • Evaluate coefficient of variation across replicates

  • Perform day-to-day reproducibility testing

  • Implement automation-compatible protocols to reduce variability

When designing multiplexed assays, carefully select antibody pairs that don't compete for overlapping epitopes and have minimal cross-reactivity with other proteins in the panel.

How does the research approach for SPBC1861.04c differ from approaches used for studying antibodies in therapeutic contexts?

The research approaches differ significantly:

• Experimental focus:

  • SPBC1861.04c research emphasizes basic cellular function and RNA biology

  • Therapeutic antibody research prioritizes efficacy, potency, and safety

  • SPBC1861.04c studies use the antibody as a tool, while therapeutic studies evaluate the antibody itself as the intervention

• Methodological differences:

  • SPBC1861.04c studies typically employ cell-based assays in model organisms

  • Therapeutic antibody research requires neutralization assays against pathogens or disease targets

  • Affinity measurements are critical for therapeutic antibodies but less emphasized for research antibodies

• Validation requirements:

  • Research antibodies need validation for specific detection applications

  • Therapeutic antibodies require extensive characterization of binding kinetics, stability, and off-target effects

  • Safety profiling is mandatory for therapeutic applications but not for research tools

• Development trajectory:

  • SPBC1861.04c antibody development follows academic research needs

  • Therapeutic antibodies undergo rigorous development pipelines with regulatory considerations

  • Epitope mapping is critical for understanding therapeutic mechanisms but optional for research antibodies

When considering methodological crossover, techniques like the cell-based inhibition assays used for screening SARS-CoV-2 neutralizing antibodies could be adapted to study protein-protein interactions involving SPBC1861.04c.